Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 12/20 | 0.47 |
| ▸ | GZMB | P10144 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556937 | 1.00 | CASP1 (0.47) | CASP1GZMBCASP3 | |
| SCHEMBL7286925 | 1.00 | CASP1 (0.47) | CASP1GZMBCASP3 | |
| SCHEMBL2556934 | 1.00 | CASP1 (0.47) | CASP1GZMBCASP3 | |
| SCHEMBL20257122 | 0.92 | CASP1 (0.49) | CASP1CASP3 | |
| SCHEMBL20257125 | 0.92 | CASP1 (0.49) | CASP1CASP3 | |
| SCHEMBL23133189 | 0.92 | CASP1 (0.49) | CASP1CASP3 | |
| SCHEMBL23133187 | 0.92 | CASP1 (0.49) | CASP1CASP3 | |
| SCHEMBL7275397 | 0.88 | CASP1 (0.41) | CASP1GZMBCASP3 | |
| SCHEMBL14345603 | 0.84 | CAPN1 (0.40) | CASP1 | |
| SCHEMBL7285000 | 0.82 | CASP1 (0.64) | CASP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | claimed |
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | claimed |
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | disclosed |
| US-11291705-B2 | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2022-04-05 | — | — | US | disclosed |
| US-20080026003-A1 | Methods for inhibiting pain | THE GENERAL HOSPITAL CORPORATION (US) | 2008-01-31 | — | — | US | disclosed |
| EP-1361897-A4 | METHODS FOR INHIBITING PAIN | GEN HOSPITAL CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040105859-A1 | Methods for inhibiting pain | GENERAL HOSPITAL CORPORATION, THE | 2004-06-03 | — | — | US | disclosed |
| EP-1361897-A2 | METHODS FOR INHIBITING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002038035-A2 | METHODS FOR INHIBITING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885GZMB 426/4885CASP3 1797/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885GZMB 426/4885CASP3 1797/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885GZMB 426/4885CASP3 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.